The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
DXCM removed three risks from its 2025 filing, including outdated COVID-19 pandemic guidance and cost-containment pressures, while substantively modifying eight risks related to manufacturing capacity, international regulatory authorization, market acceptance, and compliance. The company added no new risk factors, suggesting a consolidation rather than expansion of risk disclosures. The net effect reflects DXCM's maturation as a business, with refinements to existing risk language rather than the emergence of novel business threats.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🔴 No Match in Current Filing
We are subject to cost-containment efforts by third-party payors that could result in reduced product pricing and/or sales of our products and cause a reduction in revenue.
🔒
🔴 No Match in Current Filing
Our CGM systems currently have regulatory marketing authorization limited to individual patient home-use, and have otherwise not received clearance or approval from the FDA or other regulators for use in hospital or other in-patient facility settings, although the FDA has advised us that it will not object to the use of our CGM systems in such settings during the COVID-19 pandemic. Our potential supply of our CGM systems for use in this environment during the COVID-19 pandemic may present risks to our business.
🔒
🔴 No Match in Current Filing
The warrants related to the 2023 Notes and our common stock.
🔒
🟡 Modified
If our manufacturing capabilities are insufficient to produce an adequate supply of product at appropriate quality levels, our growth could be limited and our business could be harmed.
🔒
🟡 Modified
Failure to obtain any required regulatory authorization in international jurisdictions will prevent us from marketing our products abroad.
🔒
🟡 Modified
Our products may not achieve or maintain market acceptance.
🔒
🟡 Modified
We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.
🔒
🟡 Modified
If we experience decreasing prices for our products and we are unable to reduce our expenses, including the per unit cost of producing our products, there may be a material adverse effect on our business, results of operations, financial condition and cash flows.
🔒
🟡 Modified
Our Amended Credit Agreement imposes restrictions on us that may adversely affect our ability to operate our business.
🔒
🟡 Modified
Sustainability (including environmental, social and governance) regulations, policies and provisions could expose us to numerous risks.
🔒
🟡 Modified
Our business could be negatively impacted by evolving expectations and challenges relating to implementing sustainability (including environmental, social and governance) initiatives, setting sustainability-related goals, collecting sustainability-related data, and disclosing sustainability-related information.
🔒